Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 13/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983268 | 0.88 | GPR119 (0.49) | CHRM1CHRM3CHRM5CHRM2SMN1; SMN2 | |
| SCHEMBL84134 | 0.78 | ALDH1A1 (0.49) | CHRM1CHRM3CHRM5CHRM2SMN1; SMN2 | |
| SCHEMBL4840733 | 0.77 | KDM4E (0.46) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL11790891 | 0.76 | ALDH1A1 (0.48) | CHRM1CHRM3CHRM5CHRM2SMN1; SMN2 | |
| SCHEMBL5867974 | 0.74 | CHRM4 (0.46) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL6369665 | 0.72 | ALDH1A1 (0.47) | CHRM1CHRM3CHRM5CHRM2SMN1; SMN2 | |
| SCHEMBL9095901 | 0.72 | CHRM1 (0.49) | CHRM1CHRM3CHRM5CHRM2SMN1; SMN2 | |
| SCHEMBL8905179 | 0.72 | ALDH1A1 (0.47) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1270807 | 0.71 | LMNA (0.51) | CHRM1CHRM3CHRM5CHRM2CYP2C19 | |
| SCHEMBL10915717 | 0.71 | LMNA (0.47) | CHRM1CHRM3CHRM5CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012166-B1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2003-10-29 | — | — | EP | disclosed |
| US-6420438-B1 | FOR THERAPY OF THROMBOTIC DISEASE, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY | TULARIK LIMITED (GB) | 2002-07-16 | — | — | US | disclosed |
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6262069-B1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1012166-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999011657-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | CTRL, HPN, CTSL | CHRM1 2051/4885CHRM3 3552/4885CHRM5 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.